Sarah Larson1, Wendy Stock. 1. University of Chicago Medical Center and the University of Chicago Cancer Research Center, University of Chicago, Chicago, Illinois, USA.
Abstract
PURPOSE OF REVIEW: Despite improvements in the achievement of complete remission and progress in the supportive care of adults with acute lymphoblastic leukemia during the last decade, the majority of patients have eventually relapsed with overall survival in adult acute lymphoblastic leukemia of only 30-40%. However, the recent approach of adapting therapy according to biologic features appears to be resulting in significant progress for specific subsets of adults with acute lymphoblastic leukemia. RECENT FINDINGS: The present review highlights some of these new risk-adapted approaches focusing on recent advances in treatment of Philadelphia chromosome positive acute lymphoblastic leukemia and mature B-cell acute lymphoblastic leukemia using biologically targeted therapies, and new approaches to treatment of acute lymphoblastic leukemia in older adolescents and young adults, adopting therapeutic strategies employed in the successful treatment of children with acute lymphoblastic leukemia. A recent study that examines the role of allogeneic stem cell transplant for adults with acute lymphoblastic leukemia in first remission will also be reviewed. SUMMARY: The subset-specific approach to therapy of adult acute lymphoblastic leukemia is beginning to result in promising improvements in survival. Future improvements in survival of adults with acute lymphoblastic leukemia will depend on participation in large cooperative group trials using biologically defined protocols for this relatively rare and heterogeneous group of diseases.
PURPOSE OF REVIEW: Despite improvements in the achievement of complete remission and progress in the supportive care of adults with acute lymphoblastic leukemia during the last decade, the majority of patients have eventually relapsed with overall survival in adult acute lymphoblastic leukemia of only 30-40%. However, the recent approach of adapting therapy according to biologic features appears to be resulting in significant progress for specific subsets of adults with acute lymphoblastic leukemia. RECENT FINDINGS: The present review highlights some of these new risk-adapted approaches focusing on recent advances in treatment of Philadelphia chromosome positive acute lymphoblastic leukemia and mature B-cell acute lymphoblastic leukemia using biologically targeted therapies, and new approaches to treatment of acute lymphoblastic leukemia in older adolescents and young adults, adopting therapeutic strategies employed in the successful treatment of children with acute lymphoblastic leukemia. A recent study that examines the role of allogeneic stem cell transplant for adults with acute lymphoblastic leukemia in first remission will also be reviewed. SUMMARY: The subset-specific approach to therapy of adult acute lymphoblastic leukemia is beginning to result in promising improvements in survival. Future improvements in survival of adults with acute lymphoblastic leukemia will depend on participation in large cooperative group trials using biologically defined protocols for this relatively rare and heterogeneous group of diseases.
Authors: Guoyi Ma; Li Chong; Xing-Cong Li; Ikhlas A Khan; Larry A Walker; Shabana I Khan Journal: J Cancer Res Clin Oncol Date: 2010-02-07 Impact factor: 4.553
Authors: Susan O'Brien; Gary Schiller; John Lister; Lloyd Damon; Stuart Goldberg; Walter Aulitzky; Dina Ben-Yehuda; Wendy Stock; Steven Coutre; Dan Douer; Leonard T Heffner; Melissa Larson; Karen Seiter; Scott Smith; Sarit Assouline; Philip Kuriakose; Lori Maness; Arnon Nagler; Jacob Rowe; Markus Schaich; Ofer Shpilberg; Karen Yee; Guenter Schmieder; Jeffrey A Silverman; Deborah Thomas; Steven R Deitcher; Hagop Kantarjian Journal: J Clin Oncol Date: 2012-11-19 Impact factor: 44.544
Authors: Norma J Nowak; Sheila N J Sait; Amer Zeidan; George Deeb; Dan Gaile; Song Liu; LaurieAnn Ford; Paul K Wallace; Eunice S Wang; Meir Wetzler Journal: Cancer Genet Cytogenet Date: 2010-05
Authors: Amy M Berkman; Clark R Andersen; Branko Cuglievan; David C McCall; Philip J Lupo; Susan K Parsons; Courtney D DiNardo; Nicholas J Short; Nitin Jain; Tapan M Kadia; J A Livingston; Michael E Roth Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-06-01 Impact factor: 4.090
Authors: Michael J Burke; Nathan Gossai; John E Wagner; Angela R Smith; Veronika Bachanova; Qing Cao; Margaret L MacMillan; Heather S Stefanski; Daniel J Weisdorf; Michael R Verneris Journal: Biol Blood Marrow Transplant Date: 2012-09-06 Impact factor: 5.742
Authors: K W Pratz; E Cho; M J Levis; J E Karp; S D Gore; M McDevitt; A Stine; M Zhao; S D Baker; M A Carducci; J J Wright; M A Rudek; B D Smith Journal: Leukemia Date: 2010-06-10 Impact factor: 11.528
Authors: S Morisot; A S Wayne; O Bohana-Kashtan; I M Kaplan; C D Gocke; R Hildreth; M Stetler-Stevenson; R L Walker; S Davis; P S Meltzer; S J Wheelan; P Brown; R J Jones; L D Shultz; C I Civin Journal: Leukemia Date: 2010-08-26 Impact factor: 11.528